0 CHECKOUT

Otitis Media - Pipeline Review, H1 2015

  • ID: 3099699
  • January 2015
  • 82 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • BCO Pharma Ltd
  • Cellceutix Corporation
  • ContraFect Corporation
  • GlaxoSmithKline plc
  • Laboratorios SALVAT S.A.
  • Otonomy, Inc.
  • MORE

Otitis Media - Pipeline Review, H1 2015

Summary

This, ‘Otitis Media - Pipeline Review, H1 2015’, provides an overview of the Otitis Media’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • BCO Pharma Ltd
  • Cellceutix Corporation
  • ContraFect Corporation
  • GlaxoSmithKline plc
  • Laboratorios SALVAT S.A.
  • Otonomy, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Otitis Media Overview
Therapeutics Development
Pipeline Products for Otitis Media - Overview
Pipeline Products for Otitis Media - Comparative Analysis
Otitis Media - Therapeutics under Development by Companies
Otitis Media - Therapeutics under Investigation by Universities/Institutes
Otitis Media - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Otitis Media - Products under Development by Companies
Otitis Media - Products under Investigation by Universities/Institutes
Otitis Media - Companies Involved in Therapeutics Development
Arbor Pharmaceuticals, LLC.
BCO Pharma Ltd
Cellceutix Corporation
ContraFect Corporation
Cubist Pharmaceuticals, Inc.
GlaxoSmithKline plc
Laboratorios SALVAT S.A.
Otonomy, Inc.
Serum Institute of India Limited
Yuhan Corporation
Otitis Media - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(fluocinolone acetonide + ciprofloxacin hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCO-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
betahistine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brilacidin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CF-309 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ciprofloxacin SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2189242A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SIILPCV-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YH-1177 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Otitis Media - Recent Pipeline Updates
Otitis Media - Dormant Projects
Otitis Media - Product Development Milestones
Featured News & Press Releases
Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combination solution in the treatment of AOMT with Tympanostomy tubes
Jul 08, 2014: Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro in Pediatric Patients Undergoing Ear Tube Placement Surgery
May 08, 2014: Otonomy Completes Enrollment of AuriPro Pivotal Studies in Pediatric Patients Undergoing Ear Tube Placement Surgery
Feb 24, 2014: Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections
Dec 11, 2013: Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
Aug 20, 2013: Otonomy Announces Positive Phase 1b Results for OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
May 28, 2013: Salvat Completes Enrollment Of Phase III Study For New Combination In Acute Otitis Media In Pediatric Patients With Tympanostomy Tubes
Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections
Jun 08, 2011: Otonomy Announces Positive Preclinical Results For OTO-201
Dec 30, 2010: 13therapeutics Completes Pre-IND Meeting With FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Otitis Media, H1 2015
Number of Products under Development for Otitis Media - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Otitis Media - Pipeline by Arbor Pharmaceuticals, LLC., H1 2015
Otitis Media - Pipeline by BCO Pharma Ltd, H1 2015
Otitis Media - Pipeline by Cellceutix Corporation, H1 2015
Otitis Media - Pipeline by ContraFect Corporation, H1 2015
Otitis Media - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015
Otitis Media - Pipeline by GlaxoSmithKline plc, H1 2015
Otitis Media - Pipeline by Laboratorios SALVAT S.A., H1 2015
Otitis Media - Pipeline by Otonomy, Inc., H1 2015
Otitis Media - Pipeline by Serum Institute of India Limited, H1 2015
Otitis Media - Pipeline by Yuhan Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Otitis Media Therapeutics - Recent Pipeline Updates, H1 2015
Otitis Media - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Otitis Media, H1 2015
Number of Products under Development for Otitis Media - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Arbor Pharmaceuticals, LLC.
BCO Pharma Ltd
Cellceutix Corporation
ContraFect Corporation
Cubist Pharmaceuticals, Inc.
GlaxoSmithKline plc
Laboratorios SALVAT S.A.
Otonomy, Inc.
Serum Institute of India Limited
Yuhan Corporation

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S